Funahashi Kota, Hirose Marina, Kondo Suguru, Sano Yoshimi, Fujita Shiho, Iwata Nakao, Kitajima Tsuyoshi
Department of Psychiatry, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Department of Plastic and Reconstructive Surgery, Division of Pediatric Dentistry and Orthodontics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Fujita Med J. 2023 Aug;9(3):218-224. doi: 10.20407/fmj.2022-023. Epub 2022 Dec 27.
We evaluated the continuity and effectiveness of oral appliances (OAs) for treating obstructive sleep apnea (OSA) in a psychiatric sleep clinic, specifically focusing on mild cases and those with psychiatric comorbidity.
We retrospectively examined the medical records of 106 OSA patients treated with OA. Survival analysis was performed to assess the discontinuation of OA use. Clinical Global Impression-Improvement (CGI-I) scale were obtained from medical records. The apnea-hypopnea index (AHI), measured by polysomnography (PSG), and Epworth Sleepiness Scale (ESS) were compared between diagnosis and after post-OA treatment if a second PSG for efficacy assessment was conducted.
Among all 106 patients, Kaplan-Meier analysis estimated a discontinuation rate of 16.8% at 1 year. This tended to be higher for OSA patients with psychiatric comorbidity (22.7%) than those without (11.6%), though it was not statistically significant (=0.08). The overall rate of improvement in CGI-I scale was 37.7% and was significantly lower in OSA patients with psychiatric comorbidity (25.0%) than those without (48.3%). Among the 74 patients who underwent a second PSG, AHI and ESS were significantly lower after OA treatment for the entire group and subgroups of OSA severity at diagnosis and psychiatric comorbidity, except for ESS in the moderate OSA severity subgroup.
OA continuation was relatively good, and sleepiness was relieved by OA use, even in mild OSA patients and those with psychiatric comorbidity. However, the continuation and subjective improvement of symptoms were slightly lower in OSA patients with psychiatric comorbidity.
我们在一家精神科睡眠诊所评估了口腔矫治器(OA)治疗阻塞性睡眠呼吸暂停(OSA)的持续性和有效性,特别关注轻度病例以及合并精神疾病的患者。
我们回顾性研究了106例接受OA治疗的OSA患者的病历。进行生存分析以评估OA使用的中断情况。从病历中获取临床总体印象改善(CGI - I)量表。如果进行了第二次用于疗效评估的多导睡眠图(PSG)检查,则比较诊断时和OA治疗后的呼吸暂停低通气指数(AHI)以及爱泼华嗜睡量表(ESS)。
在所有106例患者中,Kaplan - Meier分析估计1年时的中断率为16.8%。合并精神疾病的OSA患者(22.7%)的中断率往往高于未合并精神疾病的患者(11.6%),尽管差异无统计学意义(=0.08)。CGI - I量表的总体改善率为37.7%,合并精神疾病的OSA患者(25.0%)的改善率显著低于未合并精神疾病的患者(48.3%)。在接受第二次PSG检查的74例患者中,除中度OSA严重程度亚组的ESS外,整个组以及诊断时OSA严重程度和精神疾病合并症亚组在OA治疗后AHI和ESS均显著降低。
OA的持续使用情况相对良好,即使在轻度OSA患者和合并精神疾病的患者中,使用OA也能缓解嗜睡症状。然而,合并精神疾病的OSA患者在症状持续和主观改善方面略低。